Paclitaxel albumin injection, also known by its brand name Abraxane, is a unique formulation of the chemotherapy drug paclitaxel. The primary factor that sets paclitaxel albumin injection apart from other paclitaxel formulations is its use of albumin, a human protein, as the drug delivery system [1].

Traditional paclitaxel formulations, such as those sold under the brand name Taxol, rely on chemical solvents like polyoxyethylated castor oil and ethanol to enable the drug's delivery into the bloodstream [2]. These solvents can cause side effects like hypersensitivity reactions, necessitating premedication with corticosteroids and antihistamines [3].

In contrast, paclitaxel albumin injection leverages albumin's natural ability to bind and transport drugs throughout the body [1]. By binding paclitaxel to albumin, the drug can be delivered more efficiently, potentially reducing side effects and improving treatment outcomes [4].

Moreover, paclitaxel albumin injection has been shown to have a higher maximum tolerated dose and faster rate of paclitaxel delivery compared to solvent-based paclitaxel formulations [5]. This allows for more flexible dosing schedules and potentially improved treatment outcomes.

In summary, paclitaxel albumin injection is unique due to its use of albumin as a drug delivery system, which enables higher doses, faster delivery, and potentially reduced side effects compared to traditional solvent-based paclitaxel formulations [1][2][3][4][5].

Sources:
[1] DrugPatentWatch.com. (n.d.). Abraxane (Paclitaxel Albumin-Stabilized Nanoparticle Formulation). Retrieved from <https://www.drugpatentwatch.com/drugs/abraxane>
[2] Cancer Research UK. (2019, August 22). Paclitaxel. Retrieved from <https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs/paclitaxel>
[3] National Comprehensive Cancer Network. (2020). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 2.2020. Retrieved from <https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf>
[4] Gradishar, W. J. (2006). New Developments in the Treatment of Metastatic Breast Cancer. Mayo Clinic Proceedings, 81(5), 633–643. <https://doi.org/10.4065/81.5.633>
[5] Desai, N., Koberle, A., Chang, J., Bender, R., & Govindan, R. (2013). Phase I Study of Nab-Paclitaxel in Combination with Carboplatin and Bevacizumab in Patients with Advanced Solid Tumors. Investigational New Drugs, 31(2), 421–428. <https://doi.org/10.1007/s10637-012-9932-5>